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Abstract 
Plants have a long history as a source of nutrition and medication. In the last few 
decades, interest has also emerged in using plants as a production system for protein 
pharmaceuticals, in part due to possible scale-up- and safety-benefits with this 
method of production. One class of protein pharmaceuticals for which the use of a 
plant production system might be particularly interesting is hemoglobin-based 
oxygen carriers (HBOC’s), a type of pharmaceutical intended to function as an 
alternative to donated blood in clinical situations. HBOC’s face many safety and 
production challenges, that have so far prevented widespread use, and production in 
plants could perhaps help towards solving these problems. In this thesis, we aimed 
to express and characterize proteins of interest with the goal of using them in oxygen 
therapeutics, using transient expression in Nicotiana benthamiana. The expressed 
recombinant proteins were based on human myoglobin (Mb), fetal hemoglobin 
(HbF) and α1-microglobulin (A1M). The proteins were successfully expressed in 
tobacco leaves and the purified proteins displayed their respective functional 
activity. The plant expression system thus showed its efficacy, and was capable of 
supplying the critical heme for Mb and Hb production, something that may also have 
implications for using plants as a source of nutritional iron. While more work is 
needed, the results help to show the feasibility of using heme-binding proteins 
produced in plants for pharmaceutical uses, something that was also underlined by 
animal- and cell-tests. 
Keywords: Molecular farming, heterologous expression, transient expression, 
oxygen therapeutic, HBOC, hemoglobin, myoglobin, α1-microglobulin, A1M, 
XTEN. 
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 Abstract 
Växter har en lång historia som en källa till läkemedel och näring. Under de senaste 
decennierna intresse också dykt upp för att använda växter som ett 
produktionssystem för proteinläkemedel, delvis på grund av möjliga uppskalnings 
och säkerhetsfördelar med denna produktionsmetod. En klass av proteinläkemedel 
för vilket produktion i växter kan vara särskilt intressent är hemoglobinbaserade 
syrebärare (HBOC), en typ av läkemedel som är avsedd att fungera som ett alternativ 
till donerat blod i kliniska situationer. HBOC:s står inför många säkerhets- och 
produktionsutmaningar, som hittills har förhindrat utbredd användning, och 
produktion i växter kan kanske bidra till att lösa dessa problem. I detta projekt 
syftade vi till att uttrycka och karakterisera proteiner av intresse i en HBOC kontext, 
genom transient uttryck i Nicotiana benthamiana. De uttryckta rekombinanta 
proteinerna baserades på humant myoglobin (Mb), fetalt hemoglobin (HbF) och α1-
mikroglobulin. Dessa proteiner uttrycktes framgångsrikt i växten och de renade 
proteinerna visade sina respektive funktionella aktiviteter. Den naturliga biosyntesen 
i växten visade således sin effektivitet och kunde leverera det kritiska hemet för Mb- 
och Hb-produktion, något som också kan ha konsekvenser i 
järnnutritionssammanhang. Även om mer arbete behövs så så visar resultaten på 
möjligheten av att använda hembindande proteiner som produceras i växter för 
farmaceutiskt bruk, något som också underströks av djur- och celltester. 
Keywords: Molekylärt jordbruk, hetrolog expression, transient expression, läkemedel 
för syrgastransport, HBOC, hemoglobin, myoglobin, α1-microglobulin, A1M, XTEN 
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The principal aim of this thesis work was to explore the possibility of using 
plants as a production system for heme binding proteins useful for oxygen 
therapeutics, thereby contributing to the overall objective of taking this class 
of compounds from a promising concept to a therapeutic reality. The hope is 
also to help meet other nutritional and clinical needs for which heme proteins 
produced in plants could be part of a future solution. 
 
The specific objectives of this thesis were: 
 
• To transiently express the proteins of interest, myoglobin (Mb), α-γ 
fusion fetal hemoglobin (fHbF), α1-microglobulin (A1M) and 
XTENylated fusion fetal hemoglobin (XTEN-fHbF) in N. 
benthamiana for plant-based production of these proteins. 
• To purify and characterize the chemical and physical properties of 
the proteins of interest, with an emphasis on functions and 
properties relevant to pharmaceutical use in an oxygen therapeutic 
context. 
  
1. Aim and Objectives 
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2.1 Molecular farming – plants as a factory for protein 
pharmaceuticals 
The use of plants for medical applications most likely predates civilization, 
with the earliest written evidence found on ancient Sumerian clay tablets 
(Petrovska, 2012). Even in modern times the metabolites of plants have been 
a good source of leads for drug development (Dias et al., 2012), with a 
relatively recent example being artemisinin for use against malaria (Su & 
Miller, 2015). The advent of molecular medicine and recombinant 
technology opened new possibilities however and plants came to be of 
interest as a production platform for recombinant proteins for pharmaceutical 
and other applications, with early examples of this starting to emerge in the 
late 80’s and early 90’s (Sijmons et al., 1990; Hiatt et al., 1989; Barta et al., 
1986). The concept of harnessing agriculture and plants to produce protein 
based molecular products like pharmaceuticals in large quantities became 
known as molecular farming (Fischer et al., 1999a), and it has long attracted 
interest due to the promise of large-scale and low-cost production of these 
important products (Buyel, 2019). Molecular farming has since been used 
for the production of pharmaceutical candidates (Yao et al., 2015), and has 
had some success for the production of proteins for use as industrial and 
research reagents, cosmetics and for veterinary products (Tschofen et al., 
2016). Approval of plant-produced therapeutics has been limited however 
and in a recent review the commercial history of molecular farming was 
described in terms of a “Gartner hype cycle”. That is, as an initial hype 
following the emergence of the new platform, followed by disillusionment 
and an eventual renewal of interest during the last decade as the technology 
advances (Fischer & Buyel, 2020). 
2. Introduction 
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When compared to other expression systems, the relatively low production 
cost, high scalability and low risk of contamination are commonly held up 
as the primary advantages of the plant expression systems, in particular 
compared to high cost mammalian expression systems typically relying on 
cell culture. Compared to low cost microbial systems, i.e. bacteria and yeast, 
plants are often considered to have the edge when it comes to product quality 
(Tripathi & Shrivastava, 2019; Yao et al., 2015; Ma et al., 2003). Being 
advanced eukaryotic organisms, plants are considered better capable of 
correctly folding and assembling complex proteins than bacteria (Yao et al., 
2015) and are capable of eukaryotic post-translational modifications, such as 
glycosylation (Strasser, 2016; Yao et al., 2015). The plant N-glycosylation 
is in fact relatively mammalian-like, compared to that seen in yeast (Strasser, 
2016), and is amenable to genetic engineering to further increase the 
similarity (Schoberer & Strasser, 2018; Castilho & Steinkellner, 2012). The 
low contamination risk and safety aspect of plant-based production comes 
from the lack of bacterial endotoxins and inability of human pathogens such 
as viruses to replicate (Buyel, 2019; Tripathi & Shrivastava, 2019; Sabalza 
et al., 2014). An interesting possibility is also raised by molecular farming 
in edible crops: edible vaccines, which would result from recombinant 
expression of antigens in edible plants (Haq et al., 1995; Mason et al., 1992). 
 
However, several challenges have also been encountered. The frequently 
occurring low yields of expressed protein resulting from nuclear 
transformation of plants has been pointed out as a cause that has held back 
the industry and prevented a wider adoption of molecular farming (Moon et 
al., 2019; Schillberg et al., 2019). In addition, the protein purification and 
isolation can be challenging, as plant extracts tend to have a high particle 
burden and large amounts of host cell proteins, and metabolites, such as 
phenolics. Overall, the downstream processing can amount to up to 80% of 
the production cost (Buyel, 2019). It has been argued that some of the 
challenges of plant protein purification primarily stem from the system being 
less commonly used, and hence less developed than microbial and animal 
cell production (Yao et al., 2015). Indeed, techniques for effective extraction 
and clarification, for example using screw-presses, heating and diafiltration, 
have been shown to be effective in mitigating these issues (Buyel, 2019). As 
for edible vaccines, the effectiveness of this type of product has been 
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demonstrated, but it has also become clear that controlling the delivered dose 
in a reliable way can be difficult (Moon et al., 2019). The debate over GMO 
has been an issue, due to concerns over the possibility of contamination of 
food crops with transgenic material used for molecular farming, which has 
presented obstacles to using food crops for molecular farming (Yao et al., 
2015; Paul & Ma, 2011). Biocontainment has also been an issue and is an 
important consideration for molecular farming (Clark & Maselko, 2020). 
 
Over the years, a large number of techniques have been developed for plant 
protein expression, and various species have been considered as production 
systems (Moon et al., 2019; Paul & Ma, 2011; Twyman et al., 2003). Further 
considerations include for example the type of tissues used for the 
production, i.e. cell, root, leaf or seed, and culture conditions, which could 
be open-field, or closed culture, in turn based on either greenhouses, 
bioreactors or hydroponics (Moon et al., 2019). These variations could be 
considered a strength of the plant expression systems, as there are many 
options to choose from to fit a given application. Plants that have been used 
for molecular farming purposes include for example potato (Sijmons et al., 
1990), tobacco (Hiatt et al., 1989), maize (Hood et al., 1999), rice, safflower 
(Paul & Ma, 2011), tomato and lettuce (Moon et al., 2019). Carrot cell 
culture was used for production of recombinant glucocerebrosidase, which 
became the first plant produced pharmaceutical to be approved by the FDA 
(Yao et al., 2015). Factors such as yield, storage stability and containment 
vary depending on the crop system (Stoger et al., 2002). The type of tissue 
for accumulation of a protein of interest can also be important, targeting the 
expression to seeds for example, could improve storage stability (Yao et al., 
2015).  
 
Strategies for heterologous expression of proteins in plants include nuclear 
transformation, chloroplast transformation and transient expression (Paul & 
Ma, 2011). Nuclear transformation of plants is a common approach for 
molecular farming and often relies on Agrobacterium-mediated 
transformation or particle bombardment (Ma et al., 2003). Following 
introduction of the gene of interest into the plant genome, plants with the 
gene of interest can be generated and selected for, and transgenic seeds can 
be retrieved for future use (Chen et al., 2013). Chloroplast transformation is 
an interesting alternative to nuclear transformation due to the high expression 
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levels that are often achievable (Ahmad et al., 2016; Daniell, 2002; Bock, 
2001), with levels up to 70% of total soluble protein reported (Oey et al., 
2009). It also offers a degree of biocontainment, as the plastid-incorporated 
sequence is rarely transmitted by pollen (Ahmad et al., 2016). However, the 
post-translational modifications are more limited than for nuclear 
transformation, with no access to glycosylation. The range of species is also 
more limited than for nuclear transformation (Ahmad et al., 2016). Transient 
expression techniques, using either Agrobacterium tumefaciens or virus 
vectors (Gleba et al., 2007; Fischer & Emans, 2000) are capable of very high 
protein yields, (Chen et al., 2013) and are faster than stable transformation 
techniques (Moon et al., 2019). The high yields compared to stable 
transformation are believed to be linked to the lack of positional effects when 
not inserting the gene of interest into the plant genome, as it carries the risk 
of insertion into a chromosomal region with low transcriptional activity 
(Chen et al., 2013). The downside is primarily a more limited scalability, as 
the gene is not stably integrated in the plants, which instead needs to be 
treated to induce expression, rather than grown from transgenic seeds, which 
increases labor input. The advantages of the viral vectors and 
Agrobacterium-mediated transient expression have also been combined in 
the use of deconstructed viruses delivered into the plant cell by 
Agrobacterium (Komarova et al., 2010; Gleba et al., 2007). This strategy, 
which was the focus in this thesis, will be described in more detail in section 
2.3. 
2.2 Oxygen therapeutics – a long sought goal 
In the 17th century, the first well-documented transfusions of blood into 
humans took place, in an attempt to treat mental illness. The blood used came 
from calves and lambs, and the procedure had soon earned a bad reputation. 
It was only in the early 20th century, with a more thorough understanding of 
biology in general and the discovery of anticoagulants and blood groups in 
particular (not to mention species differences) that blood transfusions could 
become the staple of modern medicine that it is today (Giangrande, 2000). 
Even with the knowledge we have today donated blood is not simple to use 
for as a medication, however. It requires cross-matching between the patient 
and donor, a steady supply of healthy donors and can only be stored for a 
limited time. It can be logistically challenging to meet variations in demand 
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due to emergencies, and it can transmit infectious disease, for which 
expensive testing is required (Mozzarelli et al., 2010). There are also 
occasional complications following treatments (Chen et al., 2009). The HIV 
epidemic of the 1980s highlighted the risks of disease spread in particular 
(Kresie, 2001). These issues have motivated the search for alternatives to 
donated blood for transfusion use, intended to provide the oxygen delivery 
capability normally provided by red blood cells (RBC’s) which have been 
termed “blood substitutes”, or oxygen therapeutics (Alayash, 2004).  
 
Different concepts have been considered to fulfill this role. These include 
RBC’s grown from stem cells in vitro (Giarratana et al., 2011), artificial 
RBC’s, where Hb is encapsulated in artificial structures (Chang, 2006), such 
as liposomes (Phillips et al., 1999) or polymer membranes (Sen Gupta, 
2019), perfluorocarbon based oxygen carriers (PFCOC), which rely on the 
biologically inert perfluorocarbon to dissolve oxygen (Castro & Briceno, 
2010). Finally there is also hemoglobin based oxygen carriers (HBOC’s), 
which rely on, generally for the purpose chemically or genetically altered, 
Hb protein (Alayash, 2004). All these oxygen therapeutic strategies have had 
challenges of their own. (Bouhassira, 2012; Castro & Briceno, 2010; 
Alayash, 2004). PFCOC’s are for example are not miscible with water and 
therefore needs emulsifiers to be added (Castro & Briceno, 2010), they have 
been known to affect to the reticuloendothelial system, and cause adverse 
effects like stroke and the only PFCOC to be approved for human use by the 
FDA (Fluosol-DA 20) was discontinued in 1994 (Henkel-Honke & Oleck, 
2007).  
 
HBOC development has faced similar challenges. Hemoglobin (Hb) is a 
heterotetrameric heme-protein (Park et al., 2006; Hill et al., 1962) that is 
normally contained inside RBCs. Human Hb has evolved to be an effective 
oxygen transporter, but presents a danger, when not confined in its natural 
environment in the RBCs (Quaye, 2015). Many of the downsides and 
challenges of using donated blood, such as the need to match blood groups 
and the short storage time, are due to the RBCs rather than the Hb protein 
itself, however, and a key challenge for the HBOC pharmaceutical concept 
is to safely use Hb when not contained in the RBC (Alayash, 2004). This is 
not trivial however, one test that illustrates the danger of free Hb was 
performed by the US navy in the 1950s, where infusions of Hb administered 
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to anemic or febrile sailors resulted in complications including hypertension 
and signs of renal damage (Chen et al., 2009). Three main types of 
mechanisms have been proposed to explain the toxicity of free Hb, which 
involve nitric oxide scavenging, oversupply of oxygen and oxidative 
reactions mediated by the heme (Alayash, 2019). Nitric oxide acts as a 
vasodilator, and its scavenging by Hb can lead to blood vessel constriction 
(Alayash, 2019). When not contained in the Fe2+ oxidation state by 
antioxidants and enzymes in the RBC, Hb can rapidly undergo autoxidation 
reactions, which results in generation of reactive oxygen species (ROS), and 
can lead to Hb unfolding and the release of free heme (Alayash, 2019), which 
is in turn also toxic (Kumar & Bandyopadhyay, 2005). Free Hb also tends to 
dissociate into its dimers, which are cleared quickly by renal filtration (Bunn 
et al., 1969), causing kidney damage (Gladwin et al., 2012). The small size 
also allows for extraversion of Hb from the blood vessels, where it spreads 
into other tissues causing damage (Schaer et al., 2013). To prevent damage 
associated with free Hb and heme, there are defense mechanisms, such as the 
Hb scavenger haptoglobin, and heme scavengers, such as hemopexin (Schaer 
et al., 2013).  
 
For the abovementioned reasons, the production of a safe and effective 
HBOC necessitates modifications of the Hb molecule chemically or by 
genetic engineering. Strategies that have been tried in clinical tests in humans 
include PEGylation (Sanguinate, MP), chemically- (HemAssist) or 
biologically- (Optro) cross-linked Hb and Hb polymerization (Polyheme, 
Hemopure, Hemolink) which have primarily aimed to stabilize Hb, 
preventing dissociation into dimers and to improve the ability of the 
molecule to transport oxygen (Alayash, 2019). The oxygen affinity and other 
factors vary between these HBOCs (Alayash, 2019), and various safety 
issues have been encountered during clinical (Silverman & Weiskopf, 2009) 
or preclinical testing (Buehler & Alayash, 2004) of HBOC candidates. 
Development continues however with new emerging concepts (Alayash, 
2019; Ferenz & Steinbicker, 2019). Recombinant technology in particular 
could offer many possibilities for further protein engineering of Hb, allowing 
for more control over properties such as stability, oxidation, and NO 
scavenging (Varnado et al., 2013). Recombinant production, using low cost 
expression systems such as E. coli is challenging however, with issues such 
as heme-supply, heme-orientational disorder and misfolding (Varnado et al., 
2013). Production of HBOC molecules in plants with recombinant 
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techniques could thus be an interesting option to explore, which has been 
previously attempted with stable expression, though with a very low reported 
yield (Dieryck et al., 1997).  
2.3 Transient expression of heme-binding proteins in N. 
benthamiana 
2.3.1 Production of heme proteins in plants 
As discussed in section 2.1, plants have several advantages for the production 
of pharmaceutical proteins in plants. The heme synthesis capacity of plants 
provide a further benefit for recombinant heme-protein production. In plants, 
heme is primarily synthesized in the chloroplast, from where it can be 
exported to the cytosol, and shares most of its biosynthetic pathway with 
chlorophyll (Brzezowski et al., 2015). Plants also produce monomeric plant 
Hbs (phytoglobins), involved in for example NO regulation and the oxygen 
supply of nitrogen fixing root nodules (Hoy & Hargrove, 2008). For this 
reason, plants could be expected to be capable of supplying heme for 
incorporation into heterologously expressed heme-proteins without the 
external addition of heme. Apart from pharmaceutical applications, 
recombinant expression of heme-proteins in plants could perhaps also have 
nutritional applications, due to the high bioavailability of heme iron (Hurrell 
& Egli, 2010).  
2.3.2 Proteins of interest 
In this thesis, we have focused on a few heme-binding proteins that we 
considered of particular interest for expression in plants. In this section, these 
proteins will be briefly introduced. 
Myoglobin 
Myoglobin (Mb) is mainly present in the muscle tissues of vertebrates and 
has important functions in the oxygenation of tissues (Wittenberg & 
Wittenberg, 1987) and in regulating the nitric oxide signaling (Wittenberg & 
Wittenberg, 2003). Animal Mb it is also an important nutritional source of 
bioavailable heme-iron (Hurrell & Egli, 2010). As a simple monomeric 
heme-protein, Mb is a good candidate for testing the plant production 
systems’ capability and capacity for recombinant heme-proteins. While Hb 
folding in RBCs is dependent on chaperones to stabilize the α-chain (Kihm 
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et al., 2002), Mb folding is not known to be dependent on such additional 
factors. As plants are also capable of producing similar monomeric Hbs, Mb 
production should be within its capability. In addition to helping to show the 
capability of the production system, recombinant Mb production in plants 
could be interesting for iron nutrition purposes or for the study of heme 
biosynthesis. Mb might also be of interest for oxygen therapeutic purposes 
in the future, perhaps in combination with other heme proteins.  
Fetal hemoglobin 
Hemoglobin (Hb) has a long history as a focus in the development of oxygen 
therapeutics (Chen et al., 2009). In addition to the capabilities shared with 
simpler heme proteins, i.e. binding and release of gaseous-ligands to its heme 
(Antonini & Brunori, 1971), Hb´s tetrameric structure allows for a variable 
oxygen affinity. This is due to a responsiveness to pH and to the ligand 
binding status of the other subunits of the holo-protein, i.e. cooperative 
binding (Eaton et al., 1999; Bohr et al., 1904). Fetal Hb (HbF) is a variant of 
Hb that is expressed primarily in the fetus, and only at very low levels in 
adult humans, it has the same two α-subunits as the adult Hb, but features 
two γ-subunits instead of the β-subunits (Sankaran et al., 2010). Another 
factor that affects the oxygen affinity of Hb is the concentration of 
diphosphoglycerate (DPG) (Tomita, 1981; Benesch et al., 1968). HbF has a 
higher oxygen affinity in vivo, due to a lower affinity for DPG, which helps 
in the transfer of oxygen from the maternal blood stream to the fetus (Simons 
et al., 2018). HbF has been suggested to have beneficial properties for HBOC 
production, such as a lower tetramer dissociation constant (Yagami et al., 
2002), and has been recently considered as an interesting alternative HBOC 
platform (Simons et al., 2018; Ratanasopa et al., 2016). 
α1-Microglobulin 
α1-Microglobulin (A1M) is a blood plasma protein believed to have multiple 
protective functions, acting as a heme scavenger, a radical scavenger and a 
reductase (Åkerström & Gram, 2014; Olsson et al., 2012). For this reason, 
A1M has attracted interest as a potential protein pharmaceutical, as a 
possible treatment for preeclampsia and acute kidney injuries during heart 
surgery (Gunnarsson et al., 2017). In conjunction with HBOC’s, A1M or 
other protective proteins such as hemopexin and haptoglobin could be 
interesting additives in order to reduce toxicity (Alayash, 2014; Schaer et al., 
2013). As a heme scavenger, A1M could bind to the reactive free heme 
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molecules that can be released by degrading heme-proteins. As free heme is 
highly toxic (Belcher et al., 2010; Kumar & Bandyopadhyay, 2005), and has 
been suggested to be a significant contributor to the toxic effects observed 
for HBOC’s (Alayash, 2019; Alayash, 2014) co-administration with heme-
scavengers could be a promising approach.  
2.3.3 Transient expression in N. benthamiana 
Tobacco (Nicotiana tabacum) and its Australian relative Nicotiana 
benthamiana are popular choices for plant molecular farming, and N. 
benthamiana in particular has been widely used for expressing recombinant 
proteins for vaccines or other pharmaceutical purposes using agroinfiltration 
(Chen et al., 2013). The advantages of these plant species lie both in a 
relatively high biomass yield per acre (Buyel, 2019) and in the fact that they 
are not food crops, thus avoiding risks of potential contamination with 
recombinant material (Chen et al., 2013). N. benthamiana has an additional 
advantage as it is very susceptible to plant virus propagation (Yang et al., 
2004), and has often been used as a model system for studying plant viruses 
(Goodin et al., 2008).  
The soil bacterium, Agrobacterium tumefaciens has the natural ability to 
insert its transfer DNA (T-DNA) on the tumor inducing (Ti) plasmid into the 
plant genome and it has long been harnessed for plant genetic engineering 
purposes (Gelvin, 2003) (Figure 1A). This ability has been further adapted 
to a biotechnological role by rational design, such as the division of the Ti-
plasmid into two complementary plasmids (Hoekema et al., 1983). The 
development of expression systems combining the advantages of 
Agrobacterium with those of plant viruses by incorporating a deconstructed 
virus, or viral elements, in the T-DNA of Agrobacterium for delivery has 
also been shown to be a valuable strategy (Peyret & Lomonossoff, 2015; 
Gleba et al., 2014). Agrobacterium can be used both for stable 
transformation and for transient expression in plants (Chen et al., 2013). 
Agrobacterium-mediated transient expression is a comparatively quick and 
convenient method to test expression of heterologous proteins in plants 
(Sheludko, 2008; Fischer et al., 1999b), and is capable of high yields of 
recombinant protein (Chen et al., 2013; Schellenberger et al., 2009). 
 
The viral vectors offer several advantages for transient expression and 
different types of such vectors have been developed, based on different types 
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of plant viruses, they are often engineered for delivery by Agrobacterium 
(Hefferon, 2017; Komarova et al., 2010). Two examples of vectors designed 
for delivery by Agrobacterium that contain viral elements are the pJL-TRBO 
(Lindbo, 2007) and pEAQ-HT vectors (Sainsbury et al., 2009). The pJL-
TRBO vector is based on the tobacco mosaic virus (TMV). It carries a 
cauliflower mosaic virus (CaMV) 35S promoter for high expression. The 
TMV sequence has been further modified by deletion of the capsid protein 
gene, which both increases the agroinfection efficiency and improves 
biocontainment by preventing plant-to-plant spread. The vector still contains 
other TMV genes, for replication and cell-to-cell movement (Figure 1B) 
however, that allows the vector to spread throughout an infected leaf 
(Lindbo, 2007).  
 
The pEAQ-HT vector was designed following the finding that vectors based 
on the cowpea mosaic virus (CPMV) RNA-2 allowed high expression of 
recombinant proteins in infected plants even without the presence of the 
RNA-1 component required for replication (Sainsbury et al., 2009; 
Sainsbury & Lomonossoff, 2008). The observation implied that the 
untranslated regions of the CPMV RNA-2 enhanced the expression 
(Sainsbury et al., 2009; Sainsbury & Lomonossoff, 2008), something that it 
has also recently been possible to improve upon by rational design (Peyret et 
al., 2019). The pEAQ-HT vector retains only a modified version of the 5’ 
and 3’ non-translatable regions of the CPMV RNA-2, with a large part virus 
sequence removed, and other elements for high expression such as CaMV 
35S promoters, and a P19 gene added. While the pEAQ-HT thus lacks the 
virus capabilities of replication and spread, the deletion allows it to avoid 
disadvantages with such systems, such as the possibility of introducing errors 
in the sequence due to the low fidelity of viral RNA dependent RNA-
polymerase (Castro et al., 2005) while retaining a high yield (Sainsbury et 
al., 2009).  
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Figure 1. Schematic figure showing T-DNA transfer from an Agrobacterium 
to a plant cell. (A) Native Agrobacterium transfers the T-DNA complex for 
insertion of its genes into the plant genome, followed by production of opines 
for use as a nutrient by the Agrobacterium, and growth hormones auxin and 
cytokinin, for inducing tumor formation (Gelvin, 2003). (B) Genetically 
engineered Agrobacterium with a binary vector configuration, where 
separate plasmids carry the T-region and the virulence genes that help the 
transfer of the T-complex, transferring its T-DNA, containing viral elements, 
to a plant cell. The T-DNA here generates an RNA replicon, capable of 
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replication and cell-to-cell movement, and generation of the protein of 
interest through translation (based on the pJL-TRBO vector). (Illustration by 
Magnus Carlsson, A: design based on image from 
(www.universiteitleiden.nl), B: modified from A based on (Lindbo, 2007)). 
2.3.4 Agroinfiltration and agrospray 
Transfer of Agrobacterium harboring vectors and genes of interest into plant 
leaf tissues can be done using three different methods, agroinfiltration, 
vacuum infiltration and agrospray (Figure. 2). The most common used 
method, agroinfiltration relies on pushing an Agrobacterium suspension 
through the stomata of the leaves using a syringe without a needle (Chen et 
al., 2013). While this is an effective method for testing expression and for 
small-scale production, it is labor intensive and thus cost-inefficient for 
larger scale production. Two methods, vacuum infiltration (Chen et al., 
2013) and agrospray, i.e. spray application of Agrobacterium (Hahn et al., 
2015; Azhakanandam et al., 2007), have been developed to be better suited 
to large scale production. In contrast to agroinfiltration, which relies mainly 
on manual work, vacuum infiltration relies on rapid pressure change to force 
an Agrobacterium suspension into the leaf, and is more easily automated 
(Chen et al., 2013). Agrospray is gentler than the first two methods as its 
entry is based on diffusion through the stomata in the presence of surfactants 
rather than force (Hahn et al., 2015). Although a smaller amount of 
Agrobacterium suspension likely enters the leaf, the replication ability of 
viral vectors such as pJL-TRBO, is likely to compensate for this. Unlike 
vacuum infiltration, agrospray does not require machinery, although suitable 
facilities would still be necessary, and additional safety precautions are 
probably warranted due to the possibility of Agrobacterium suspension 
droplets being present in air during the spraying. For paper I and paper II the 
agrospray method was used to show the feasibility of this method for large-
scale production in the future. Figure 2 illustrates the techniques discussed 
here.  
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Figure 2. Photographs illustrating techniques for introducing Agrobacterium 
suspensions into leaves of N. benthamiana. Left: syringe agroinfiltration (photo: 
Per Snell). Top right: agrospray, application of Agrobacterium suspension using 
spray by a hand sprayer (photo: Magnus Carlsson). Bottom right: vacuum 
infiltration, where the aerial part of a tobacco plant has been submerged in 
Agrobacterium suspension inside a vacuum chamber (photo: Magnus Carlsson).  
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3.1 Construct design considerations 
3.1.1 Myoglobin (Paper I) 
Two constructs of Mb were designed for expression in N. benthamiana, one 
for cytosol accumulation and one targeted to the chloroplast, by attachment 
of the N. tabacum rubisco small subunit chloroplast targeting peptide 
(Uniprot nr. P69249 (UniProt Consortium, 2019)). Targeting the expression 
to the chloroplast might be beneficial due to the organelle’s involvement in 
heme biosynthesis (Brzezowski et al., 2015), which may have implications 
for heme availability. It has been suggested, based on observations of 
tetrapyrrole synthesis regulatory mechanisms that the two variants of 
ferrochelatase responsible (FC1 and FC2) might produce separate pools of 
heme for use either in the chloroplast photosynthetic machinery (FC2) or for 
general use within the cell (FC1) (Woodson et al., 2011). The response to 
high levels of heme-chelating Mb might therefore depend on the site of its 
accumulation. 
3.1.2 Fetal Hemoglobin (Paper II, IV) 
Two strategies were used in this thesis work to modify HbF to meet different 
challenges. One challenge of producing Hb is that the free Hb α-subunit is 
unstable and cytotoxic (Mollan et al., 2010). Careful control to ensure equal 
amounts of α- and β-subunits is therefore required to avoid damage (Voon & 
Vadolas, 2008) and a dedicated chaperone, α-Hb stabilizing protein, helps 
with this in case of the native expression in red blood cells (Kihm et al., 
2002). To help ensure higher yields and equal expression of the polypeptide 
chains in the plant during expression, the α-chain was genetically fused with 
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a short flexible 12 amino acid linker (4xGGS) to the γ-chain. In addition to 
this, the larger minimum size may also be beneficial as a way to increase the 
molecules circulatory half-life, due to the decreased permeability of the 
glomerular membrane to larger molecules (Scott & Quaggin, 2015). This 
strategy is expected to ensure a very rapid combination of the two fused 
subunits into a dimer equivalent as it folds, stabilizing the α-chain. This 
approach has been shown to work better for expression of HbF in a bacterial 
expression system (Ratanasopa, 2015). This strategy was used for Paper II 
and IV.  
A major design challenge for HBOCs is the toxicity and short half-life of Hb 
not contained in RBC’s (Alayash, 2014), and various techniques have been 
used to attempt to adapt the native proteins properties, including chemical 
modifications such as PEGylation and genetic fusion strategies (Alayash, 
2019). In an attempt to improve the physicochemical and pharmacokinetic 
properties of the plant-produced fHbF we tested fusing it to an XTEN peptide 
(Paper IV), something that has also shown promise when produced in E. coli 
(Chakane, 2017). XTEN is a hydrophilic and negatively charged peptide 
designed to mimic the properties of PEGylation of a protein or peptide 
pharmaceutical, and thus enhance its circulatory half-life (Podust et al., 
2016; Schellenberger et al., 2009). Unlike PEGylation the genetic fusion of 
an XTEN sequence does not require additional processing steps (Jevsevar et 
al., 2010), with resulting drawbacks when it comes to cost and yield. It has 
also been argued that XTEN could have an advantage when it comes to 
biodegradation (Podust et al., 2016; Haeckel et al., 2014), although the poor 
biodegradability of PEG is still debated (Ulbricht et al., 2014; Jevsevar et al., 
2010). A cleavable histidine (his)-tag was also included in the N-terminal for 
some of the XTENylated sequences. 
3.1.3 α1-Microglobulin (Paper III) 
Recombinant production of α1-microglobulin (A1M) is complicated by two 
N-glycosylation sites present on the native protein (Wester et al., 2000), 
which may be important for the stability of the protein. In this study, three 
constructs were designed; one designed for cytosol accumulation, with two 
residues edited for enhanced stability (N17D and N96D) based on a previous 
study (Åkerström et al., 2019). In addition to this non-glycosylated variant, 
two versions were designed with a targeting peptide (Uniprot nr. P08299 
(UniProt Consortium, 2019)) for the secretory pathway, one of which also 
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carried a C-terminal ER-arrest peptide (KDEL) (Denecke et al., 1992; Napier 
et al., 1992), to prevent plant specific glycan motifs added downstream, in 
the Golgi apparatus (Strasser, 2016). All the constructs also carried a his-tag 
for purification and improved solubility (Åkerström et al., 2019; Kwasek et 
al., 2007). 
3.2 Transient expression of the target proteins 
In this thesis, N. benthamiana was used for expressing the proteins of interest 
through transient expression using virus derived vectors (viral vectors) 
delivered by Agrobacterium. Two vectors, pJL-TRBO (Lindbo, 2007) and 
pEAQ-HT (Sainsbury et al., 2009), were used to harbor the genes of interest. 
Expression of the P19 RNA silencing suppressor gene is often used together 
with viral vectors for ensuring high transient expression levels (Sainsbury et 
al., 2009; Lindbo, 2007). In this thesis, the P19 gene was either incorporated 
on the viral vectors used to express the target genes or expressed by a 
separate vector, which was co-infiltrated with the vector harboring the target 
genes. Standard molecular cloning techniques were used to insert the 
respective genes of interest into the viral vectors, which were then 
transformed into Agrobacterium. For transient expression, the 
Agrobacterium were delivered into plant cells mainly by agroinfiltration or 
agrospray, with the latter used primarily in Paper I and II, in order to show 
the feasibility of large-scale production. The plants used in the study were 
grown under controlled conditions at the biotron at SLU, Alnarp, and the 
plant materials used for the treatments were between 5-6 weeks old. For 
highest expression, and depending on type of proteins, the infiltrated tissue 
was harvested around 5-7 days following agroinfiltration, and around 9-14 
days for agrospray with Agrobacterium harboring the pJL-TRBO vector, 
allowing for additional time to replicate. 
3.3 Protein isolation and analysis 
3.3.1 Protein isolation 
Isolating proteins from plant material poses several challenges, including 
polyphenol oxidation, presence of high amounts of host cell proteins and a 
high particle load in the extracts, which contribute to making downstream 
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processes of isolation and purification a highly significant part of the total 
cost (Buyel, 2019). The large amounts of protein required for HBOC 
treatments would make it sensitive to costs, even more so if aiming at 
nutritional uses. We have thus put some efforts into developing efficient and 
scalable purification methodologies in this work. In Paper I, this is 
highlighted, and techniques including heat steps, ammonium sulfate 
precipitation and cross flow diafiltration were employed for the isolation of 
Mb. The excellent heat stability of Hb (Rieder, 1970) and Mb (Wan et al., 
1998) was relied upon in particular as extracts were heated to 60 oC while 
under CO gas to remove host cell proteins (Paper I, II, IV). Various 
chromatography-based techniques were then employed for obtaining final 
purity. 
3.3.2 Protein analysis – heme and spectroscopy 
While the analysis of the proteins of interest in Paper I-IV included many 
techniques, I will here focus on absorbance spectroscopy, as I found it to be 
of particular interest, due to the connection to heme-proteins and their 
functions. The proteins of interest in this thesis all have a distinctive 
absorbance spectrum and are visibly colored, either due to heme coordination 
(Antonini & Brunori, 1971) or due to the chromophore of the A1M protein, 
which confers a yellow-brown color (Kwasek et al., 2007; Åkerström et al., 
1995). In fact, the first evidence of success when expressing the heme 
proteins of Hb and Mb in plants would be found by visual observation of the 
color of the extracts. 
 
Characteristic features of heme-protein absorbance spectra include the Soret- 
(γ-) peak in the ultraviolet and the α- and β-peaks in the visible range of the 
spectrum (Antonini & Brunori, 1971). These absorption bands originate from 
the absorbance of the heme but are sensitive to the interaction between heme 
and other molecules, such as bound gaseous ligands or coordinating proteins, 
and can be used to investigate these interactions (Comer & Zhang, 2018). 
For the production of recombinant heme-protein, an absorbance spectrum 
identical or very similar to the native protein would therefore be a strong 
indicator of correct heme coordination, in turn implying correct folding of 
the protein. In paper I, II, and IV, the absorbance spectra were used to 
investigate the heterologously expressed heme-proteins and to test the ligand 
binding capability and redox status, as their respective deoxy-, oxy- carboxy- 
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and met- spectra are distinctive (Antonini & Brunori, 1971) and can be easily 
differentiated. In paper I measurements of the gradual shift from oxy- to met-
Mb spectrum were used to test the oxidative stability and determine the rate 
of autoxidation (Brantley et al., 1993). Similarly, chemical and pH stability 
could be estimated by observing the loss of heme coordination at harsh 
conditions. The binding of heme to A1M also affects its absorbance, with a 
resulting redshift of the Soret peak, which can also be affected by an N-
terminal his-tag (Karnaukhova et al., 2014). This was used in Paper III to 
test heme binding. The absorbance spectra of plant produced A1M was also 
compared to that of A1M from other sources, in order to investigate how the 
bound chromophore would depend on the expression system.  
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4.1 Myoglobin (Paper I) 
In Paper I, it was shown that the functional Mb protein could be successfully 
expressed in the leaves of N. benthamiana, following agroinfiltration or 
agrospray treatment with the pJL-TRBO vector carrying the human Mb gene. 
Both the cytosol accumulated construct and the construct targeted to 
chloroplasts were expressed at comparable levels, as indicated by SDS-
PAGE and Western blot, and displayed the expected absorbance spectrum 
(Antonini & Brunori, 1971; Hardman et al., 1966). The chloroplast targeted 
construct displayed some heterogeneity in the Western blot though, possibly 
due to incomplete removal of the signal peptide, and it was therefore not 
analyzed further. 
 
A cost-effective protocol was developed for the purification of Mb expressed 
in leaves, where most of the host cell proteins were removed by heat 
precipitation, after which the Mb protein could be concentrated and 
unwanted small molecules removed, using a cross-flow diafiltration setup. 
Precipitation of contaminants by ammonium sulfate addition, and a shift in 
pH were also performed in conjunction with the diafiltration. These 
relatively low-cost and scalable techniques ensured a comparatively high 
degree of purity and concentration of the target protein, even without the use 
of chromatography, which could be of interest in particular for nutritional 
applications. Anion-exchange chromatography was used as a final step to 
provide the high purity required for protein analysis and possible future 
medical applications. SDS-PAGE and absorbance spectroscopy analyses of 
the extracts or Mb solutions were used to determine purity. Absorbance 
4. Results and Discussion 
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spectroscopy was also used to determine the final yield of Mb following 
purification, ~210 mg/kg for agroinfiltration and about 60-80 mg/kg for 
agrospray (per fresh leaf weight). The yield of the purification was probably 
around 50-70% (for agrospray), based on estimations of the absorbance 
spectra in the extracts.  
 
While the yield of Mb protein obtained here was not exceptionally high for 
heterologous expression using the pJL-TRBO (Lindbo, 2007), it is 
interesting to note that the plant was capable of supplying this amount of 
heme. Something that has been an issue in E. coli for instance, which requires 
expression of additional proteins or supplementation of heme or its precursor 
during recombinant Hb production (Varnado et al., 2013). It was also 
capable of supplying it for both cytosol accumulated, and chloroplast 
targeted Mb, although the cellular location of heme binding event was not 
determined for the latter. In fact, no heme protein peak was discerned from 
the absorbance spectra of the extracts from the untreated N. benthamiana, 
which suggests that the produced Mb is the primary source of soluble heme-
protein present in the treated leaves. Whether the overall heme level of the 
plant was increased as an effect of the expression of Mb or whether a pool 
of heme of sufficient size for incorporation into Mb without additional 
biosynthesis was available in the plant was not determined. The results seem 
promising however, and if the increase corresponds to an increase in 
nutritionally available heme, the amounts of Mb-bound heme present in 
tobacco could mean a significant increase to the nutritional value of the plant. 
Plant produced Mb isolated with the low cost methods described here could 
also be an interesting nutritional, or culinary, additive to other foods, such as 
meat substitutes; though a thorough cost analysis would need to be done to 
assess the economic feasibility of such an approach. 
 
Following purification, the protein was shown to be functional i.e. capable 
of binding and releasing its gaseous ligands O2 and CO. The observed 
absorbance spectra conformed closely to previously reported spectra of 
sperm whale Mb (Antonini & Brunori, 1971; Hardman et al., 1966), with the 
only significant difference a small shoulder around 620 nm, probably 
resulting from a small population of degraded Mb. Data on circular 
dichroism, autoxidation rate, temperature and chemical stability were also 
collected for the purified Mb and compared to literature sources in Paper I. 
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The results from the analyses were all in line with the properties of a correctly 
folded Mb. Overall, the protein analysis indicated that the plant was capable 
of expressing a functional and correctly folded human Mb. Figure 3 shows 
Mb colored extracts and some of the steps of the purification process.  
 
 
Figure 3. Mb extraction and purification. A. Tobacco extract colored red by 
expressed Mb following agroinfiltration. B. Diafiltration setup during operation. C. 
Anion exchange chromatography of Mb, in ice bath (Photos: Magnus Carlsson). 
 
4.2 Hemoglobin (Paper II, IV) 
In Paper II the expression and analysis of fHbF is described. The expression 
in this case relied on agrospray and the pJL-TRBO vector. The protein 
extract was heat treated at 60oC similarly to Mb, and the fHbF protein was 
then purified by two steps of ion-exchange chromatography, with a 
preceding dialysis step to facilitate column binding. SDS-PAGE and 
Western blot were used to confirm expression of the target protein and 
monitor the purity. Following purification, it was determined to be 
functionally active by absorbance spectroscopy, in the presence or absence 
of its ligands. Along with the circular dichroism spectrum, this suggests that 
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the protein was correctly folded, indicating that the fusion of the subunits 
worked well. As for the Mb in Paper I, substantial amounts of heme appeared 
to be available for incorporation in fHbF and a yield of up to ~80-100 mg/kg 
highly purified fHbF was obtained.  
 
An important part of the analysis in Paper II is the animal test, which 
provides data on the circulation time of the fHbF, and serves as a proof of 
concept of a plant produced HBOC. Following injection, the fHbF appeared 
to be removed quickly via the kidneys however, in spite of the larger 
minimum molecular size of the fused protein. In addition to blood samples, 
where a decrease in the fHbF level was seen, urine samples from the mice 
were observed to contain Hb, detectable by spectroscopy, likely consisting 
of a mix of ferric and ferrous fHbF. To study the impact of the treatment on 
the mice, indicators (albumin to creatinine ratio (ACR) and blood urea 
nitrogen (BUN)) of kidney damage were analyzed and showed an increase 
following the injection, but seem to have reverted to normal levels after 24h. 
Mouse weight and body temperature did not appear to be significantly 
affected by the treatment. 
 
A important advantage of the plant system compared to bacterial expression 
systems when it comes to HBOC uses, is the lack of endotoxins (Varnado et 
al., 2013). Some endotoxin could perhaps be introduced by the 
Agrobacterium or other sources during production and purification though. 
The purified fHbF was found to contain less than 0.031 EU / mg fHbF, using 
a limulus amebocyte lysate (LAL) assay. For reference a maximum level of 
5 EU per kg of body weight per hour is indicated for intravenous 
pharmaceutical use (Petsch & Anspach, 2000). This suggests that the plant 
production platform and used purification methodology produced a very low 
level of endotoxins, possibly low enough for intravenous use in the high 
doses expected for HBOC use, though some minor additional purification 
step might be needed.  
 
XTENylated fHbF was produced with agroinfiltration as reported in Paper 
IV, primarily relying on the pEAQ-HT vector. As discussed in the materials 
and methods section this protein design is intended to prolong the circulation 
time of the fHbF when used as an HBOC. As for fHbF, heating was 
successfully used as an initial purification step, which was in this case 
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followed by immobilized metal affinity chromatography (IMAC), using the 
attached his-tag, and its functional status was confirmed by ligand binding 
and absorbance spectroscopy. The XTEN-tag did thus not appear to prevent 
the functional activity of the protein. Expression of the XTEN-tag has not 
previously been demonstrated in plants. In this study, the expression of the 
tag seemed to work well and a yield of about 60 mg/kg purified H6-XTEN-
fHbF was achieved.  
 
Dynamic light scattering was used to assess the change in hydrodynamic 
radius of the molecule. The observed values of 5.3 ± 0.2 for fHbF and 12.2 
± 0.8 for H6-XTEN-fHbF indicated a substantial increase in size. The XTEN 
tag is also expected to substantially increase the negative charges on the 
protein under physiological conditions, as the theoretical pKa changes from 
7.96 for fHbF to 4.70 for H6-XTEN-fHbF (calculated with protparam online 
tool (Gasteiger et al., 2005)). The glomerular filtration barrier tends to be 
selectively permeable based on both size and charge, with large negatively 
charged macromolecules better retained in circulation (Scott & Quaggin, 
2015). The attachment of the XTEN tag could therefore be expected to have 
a substantial effect on circulation time of the fHbF. The heat stability of fHbF 
appeared to be moderately increased by the attachment of the XTEN tag. 
Thermostability has been suggested to be another property that can be 
improved by XTENylation (Podust et al., 2016; Schellenberger et al., 2009). 
For an HBOC it would be an additional beneficial factor, particularly when 
heat steps are used for purification. Overall Paper IV showed that production 
of an XTENylated protein was possible using the plant system and that 
XTENylation could be a promising approach to improving HBOC retention 
time. However, this comes at a cost of a larger and more complex protein to 
produce.  
4.3 α1-Microglobulin (Paper III) 
As described in Paper III A1M was successfully expressed using the pJL-
TRBO vector and agroinfiltration of N. benthamiana. The untargeted, 
cytosol accumulated, construct, A1M-NB1 had a significantly higher yield 
than the ER- or apoplast-targeted A1M-NB2 and A1M-NB3. The latter two 
constructs appeared to have an increased size, perhaps indicating successful 
glycosylation. Due to its higher yield A1M-NB1 became the focus of further 
protein purification and analysis work conducted in Paper III. A1M-NB1 was 
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purified by three chromatography steps, IMAC, anion-exchange and size 
exclusion chromatography before analysis and yielded ~50 mg highly 
purified A1M-NB1 per kg fresh leaf material.  
The size exclusion chromatography also served as an analytical step, and 
showed that A1M-NB1 was present as an equilibrium of monomer, dimer 
and aggregates, which is characteristic for native A1M (Ekström & 
Berggård, 1977). Native A1M has three cysteine residues (Kaumeyer et al., 
1986), two of which form an internal cysteine bond (Mendez et al., 1982), 
while the third, Cys34, is located on the surface and believed to be involved 
in the function of A1M (Gunnarsson et al., 2017). A1M-NB1, displayed 
properties in line with this; Ellman’s test results indicated the presence of a 
single free surface cysteine while a shift in mobility in SDS-PAGE between 
reduced and non-reduced conditions, suggested that an internal cysteine 
bond is present. A1M-NB1 further displayed thermal stability properties and 
a hydrodynamic radius similar to E. coli produced A1M-035 (Åkerström et 
al., 2019), on which its sequence was based, also indicating that the plant 
produced A1M was correctly folded.  
An interesting feature of A1M is its chromophore, an unknown compound 
that binds to the protein, in a heterogeneous fashion, and confers a yellow-
brown color, and a characteristic absorbance spectrum (Kwasek et al., 2007; 
Åkerström et al., 1995). Purified A1M-NB1 similarly displayed a faint 
yellow-brown color. Absorbance and fluorescence spectroscopy revealed 
both similarities and differences pertaining to the chromophore, compared to 
A1M produced in other organisms (Kwasek et al., 2007; Åkerström et al., 
1995). The absorbance spectrum of A1M-NB1 displayed a similar overall 
shape as the E. coli produced A1M-WT (Kwasek et al., 2007) which was 
also tested, but the chromophore absorbance appeared to be elevated in 
comparison, most likely due to additional bound chromophore, and featured 
a bulge or shoulder around 390 nm unlike the bacterial A1M. With the higher 
chromophore absorbance the spectrum may therefore be more reminiscent of 
A1M from mammalian or insect cell culture sources (Åkerström et al., 
1995), although these too lack the pronounced shoulder present in the 
tobacco produced A1M. Moreover, the fluorescence spectra, following 
excitation at 350 nm, showed an increase in fluorescence around 400-550 
nm, compared to the E. coli produced sample, indicating a higher level of 
bound chromophore, similarly to the absorbance data. However the profile 
of the spectrum differed substantially compared to E. coli produced A1M 
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(Kwasek et al., 2007) and human urine A1M (Berggård et al., 1999), perhaps 
an indication that the bound compounds differ between A1M originating in 
the different organisms, and reflecting the different compounds available in 
the cells.  
In Paper III, the tobacco produced A1M-NB1 was shown to be functionally 
active. The heme binding capability of A1M (Karnaukhova et al., 2014) is 
of particular interest for HBOC applications and was tested with several 
methods. Binding of heme to proteins is detectable by observing the effect 
on the Soret peak, tryptophan fluorescence, which can be quenched, due to 
proximity of bound heme, and by gel mobility shifts (Comer & Zhang, 2018). 
When combined with varying amounts of free heme and analyzed with 
absorbance spectroscopy, a shift in the heme peak was observed, consistent 
with heme binding by A1M (Åkerström et al., 2019; Karnaukhova et al., 
2014), with the resulting heme-A1M spectra closely matching those of the 
similar, E. coli produced A1M-035 (Åkerström et al., 2019). The 
fluorescence quenching and migration shift associated with heme binding of 
A1M (Åkerström et al., 2019; Rutardottir et al., 2016; Karnaukhova et al., 
2014) were also observed, and matched the E. coli sample tested in parallel, 
though a slightly lesser effect on migration was seen, perhaps caused by the 
additional chromophore. In a further test of function, the protective effect of 
A1M-NB1 on RBCs against spontaneous, heme-induced and osmotic stress 
was evaluated. The tobacco produced A1M showed efficacy, resulting in a 
lower stress level, as has been previously demonstrated for recombinant 
A1M (Kristiansson et al., 2020). The effect against different types of stress 
implies that the mechanism is probably not attributable to heme binding 
alone, and indicates that the tobacco-produced protein is capable of 
producing the protective effects via other mechanisms, based on other 
functions attributed to A1M, i.e. radical binding and a reductase activity 
(Åkerström & Gram, 2014). 
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The proteins of tested (Mb, fHbF, H6-XTEN-fHbF, A1M) were all 
successfully expressed through transient expression in N. benthamiana using 
viral vectors delivered by Agrobacterium and displayed functional activity. 
The heme-proteins could be produced at a relatively high yield, without 
requiring supplementation of heme or heme precursor. The endotoxin level 
in the purified fHbF sample appeared to be at low or acceptable levels, even 
considering that very large doses would be expected for HBOC use, and an 
initial animal test served as a proof of concept of use of the plant produced 
Hb as an HBOC, though additional modification is required to improve the 
circulation time. Solutions based on protein engineering, such as the XTEN 
tag, could be one way forward and the demonstration in this thesis work that 
it could be expressed in the plant system without affecting the fHbF protein’s 
function is promising. The A1M protein meanwhile could have many 
possible applications due to its detoxifying heme binding and other 
functions. Based on the data in paper III, production of A1M for medical 
applications in plants appears to be feasible. The plant is capable of 
producing the A1M protein in a soluble form, and does not require refolding 
from inclusion bodies, as has been the case for production in E. coli (Kwasek 
et al., 2007) and that impact the yield negatively. The higher level of bound 
chromophore may however be a drawback. The glycosylation strategy, 
though only explored superficially in Paper III, could also be an advantage, 
and open future options for an improved product.  
Overall, the results from Paper I-IV indicate that the plant production system 
may have an important role in the future development of HBOC’s, and at 
least in the case of the heme scavenger A1M, in other pharmaceutical 
contexts. Nutritional applications could also be a possibility for plant 
produced heme-proteins, based on the data, either involving biofortification, 
or a partially or extensively purified heme-protein. Whether this is 
5. Conclusions and future perspectives 
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economically feasible will need to be evaluated in further studies, although 
the demonstration of an inexpensive isolation method for Mb might help in 
this regard. As the production scale and the purity requirements would 
inevitably be different from the type of production typically considered in 
molecular farming and the production cost might be lowered due to 
economies of scale this would need careful consideration. It is likely that 
further optimization, and perhaps use of stable transformation techniques 
would be required for nutritional applications to be feasible.  
Further increasing the yield in the transient expression system could involve 
methodological improvements to the cultivation or the agroinfection 
procedure, or improvements based on molecular techniques, such as 
engineering of the heme biosynthetic pathway. For the latter approach, a 
more thorough investigation into how the heme synthesis rate was affected 
by the massive expression of heme binding proteins following the 
Agrobacterium treatments would be a reasonable first step. Whether the 
heme biosynthesis was upregulated following the treatments and whether it 
was a limiting factor for the heme-protein production following the 
infiltration are important questions that remain to be explored. It might also 
be interesting to test expression using other methods, relying on stable 
expression instead of the burst seen during transient expression, as this might 
shed some light on whether heme biosynthesis, or other factors, such as 
protein stability are the major determinants of yield. Due to the high amounts 
that would be required in a blood substitute or nutrition context, stable 
transformation techniques might also be worth testing as a way to further 
decrease the cost of production in the plant expression systems. One 
approach that could be of interest is the stable integration of an activatable 
viral vector into the plant genome, which has been done previously with 
promising results (Dugdale et al., 2013). Chloroplast transformation could 
also be an interesting option to explore, due to its potential of achieving high 
protein yields. It might also have other advantages for the expression of 
heme-proteins, due to being the main site of heme biosynthesis and the 
presence of enzymatic systems for controlling ROS generated by the 
photosynthesis machinery (Asada, 2006). 
 
Another question that is raised by considering the plant as an expression 
system for HBOCs is whether the system could offer new possibilities for 
protein engineering. One possibility could be the use of the plant 
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glycosylation machinery as another tool to modify the properties of Hbs. The 
use of viral vectors for the production also begs the question of whether viral-
like particles (VLP’s), which are often discussed in a drug delivery context, 
and often based on plant virus capsids (Ibrahim et al., 2019; Rohovie et al., 
2017) or other similar protein structures could be interesting as artificial 
RBCs to better control toxicity and function. Using targeting peptides to 
package the HBOC into organelles, such as vaults (Muñoz-Juan et al., 2019), 
or even isolated chloroplasts might also open up possibilities for drug 
delivery. While all of these are very speculative ideas, to produce functional 
HBOCs people have tried using a wide selection of chemical or genetic 
modifications, from simple surface decoration to nanoparticles and Hb from 
humans, animals and even worms (Alayash, 2019). Plant production of 
HBOCs and other heme binding proteins could be an additional tool. 
Although safe and effective HBOC’s are elusive, if we keep trying, in the 
end, we will get there. 
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Blood donations are often critical for saving lives, bringing the blood from a 
donor to a patient in a safe and effective way is often challenging. Even if 
blood is very good at its task when it circulates in the body, it has several 
issues as a pharmaceutical, for example, it cannot be stored very long and a 
major effort is required to ensure, for example, that no diseases are 
transferred along with the blood. For this reason, people have worked on 
developing pharmaceuticals that can fulfill blood’s most acute and critical 
function, delivering oxygen. These have been termed oxygen therapeutics. 
Unfortunately, these oxygen therapeutics have mostly remained a dream, as 
it is challenging to develop a safe oxygen therapeutic. Often Hemoglobin is 
used, but without the red blood cells wherein this oxygen binding protein is 
normally found. Even if protein for pharmaceutical purposes can be 
produced in many different organisms, such as bacteria, or cultured human 
cells, plants have several abilities that make them particularly interesting, for 
example the possibility of large scale and safe production. This is particularly 
important for this type of pharmaceutical as there is so much hemoglobin in 
the blood that one needs to replace. 
In this project, we have worked on producing a number of human heme-
binding proteins for use either as such pharmaceuticals, or to assist in their 
function. To do this we have used plants, more specifically tobacco. To get 
the plant to produce the human proteins, we first inserted the DNA sequence 
that codes for the protein into a plasmid vector, a small circular DNA 
molecule, containing elements from viruses. This vector was then inserted 
into a bacterium, Agrobacterium tumefaciens, which has a natural ability to 
insert DNA into plants. The plants are then treated with the Agrobacterium, 
which makes the plant start to produce the protein that the original DNA 
sequence coded for, which can then be extracted from the plant. 
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In the thesis project, we produced myoglobin, a red heme-protein that is 
found in muscles, A1M, a heme binding protein that circulates in the blood 
and protects against toxic compounds, and different variants of hemoglobin. 
The project showed that these proteins could be produced and could be 
folded correctly in the plant, and retained its natural functions, which means 
that plants could be a good future alternative to produce this type of oxygen 
carrying pharmaceutical. As the plant was capable of supplying a sizable 
amount of heme for the heme-protein production, it could also be interesting 
to produce these proteins for iron-nutrition purposes. This is because heme 
is absorbed better by the body than other types of iron, and is otherwise 
mostly found in large amounts in meat and blood. 
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Bloddonationer är ofta kritiska för att rädda liv, men för att få blodet från en 
donator till en patient på ett säkert och effektivt sätt är ofta utmanande. Även 
om blod är väldigt bra på sin uppgift då det cirkulerar i blodomloppet så har 
det flera tillkortakommanden som ett läkemedel, till exempel så kan man inte 
lagra det särskilt länge, och det behövs en stor industri för att säkerställa 
exempelvis att smittbara sjukdomar inte kommer med. Det är därför som 
man länge har arbetat med att ta fram läkemedel som kan uppfylla blodets 
mest akuta och kritiska funktion, att leverera syre. Tyvärr så har detta i stort 
förblivit en dröm, då det är utmanande att producera en säker 
“syreleverantör”. Ofta använder man hemoglobin, fast utan de röda 
blodkroppar som normalt innesluter detta syrebindande protein, på så vis får 
man ett proteinläkemedel, liknande de som läkemedelsindustrin har stor 
erfarenhet av. Även om man kan producera protein för läkemedelsändamål i 
många olika organismer, som till exempel bakterier eller i odlade 
människoceller, så har växter flera egenskaper som gör dem särskilt 
intressenta, som till exempel möjligheten till storskalig och säker produktion. 
Detta är särskilt viktigt för denna typ av läkemedel då det finns så mycket 
hemoglobin det blod man vill ersätta. 
I det här projektet så har vi arbetat med att producera ett antal mänskliga 
heme-bindande protein för användning antingen som ett sådant läkemedel, 
eller i samband med det. För att göra detta så har vi använt växter, närmare 
bestämt tobak. För att få växten att producera de mänskliga proteinerna så 
har vi först fört in de DNA sekvenser som kodar för dem i en plasmidvektor, 
en cirkulär sträng av DNA, vilken har designats med komponenter från ett 
växtvirus. Denna plasmid, har vi sedan låtit tas upp av en bakterie, 
Agrobakterium tumefaciens, som har en naturlig förmåga att föra in DNA i 
växter. Därefter behandlar man växterna med dessa bakterier, vilka får 
Populärvetenskaplig sammanfattning 
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växten att börja producera proteinet man är ute efter vilket därefter kan 
utvinnas från växten. 
I projektet så producerade vi myoglobin, ett rött heme protein som finns i 
muskler, A1M, ett heme-bindande protein som cirkulerar i blodet och 
skyddar mot gifter, och olika varianter av hemoglobin, det protein som ger 
blodet, och de röda blodkropparna sin färg. Projektet visade att alla dessa 
proteiner kunde produceras och vikas ihop rätt i växten, och behöll sina 
naturliga funktioner, vilket betyder att växten skulle kunna vara ett bra 
framtida alternativ för att producera denna typ av syre transporterande 
läkemedel. Det är också intressent att se att växten kunde tillhandahålla så 
mycket av den järnhaltiga molekylen heme, som ju också är intressent för 
järn-nutrition, då den tas upp bättre i kroppen än andra typer av järn, och 
annars mest brukar sägas finnas i stora mängder i kött och blod. 
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Plants have long attracted interest as a platform for production of 
protein pharmaceuticals. Production in plants could be a particularly 
interesting option for hemoglobin based oxygen carriers (HBOC), 
a class of pharmaceuticals sometimes termed “blood substitute”. 
In this thesis, we have aimed to produce and characterize human 
heme-binding proteins of interest in an HBOC context, with possible 
additional nutritional uses. The proteins were successfully produced 
in Nicotiana benthamiana by Agrobacterium-mediated transient 
expression. The isolated proteins were functional and highly pure.
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